Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-11-22
2005-11-22
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007930, C435S070210, C435S810000, C436S514000, C436S506000
Reexamination Certificate
active
06967081
ABSTRACT:
This invention concerns a method for the assessment of bone fragility and fracture risk, or osteoporosis, in a person. In said method, the concentration of gamma-carboxylated osteocalcin (COC) and optionally also the concentration of intact or total osteocalcin (IOC or TOC, respectively) in a body fluid sample of said person is measured. The concentration of gamma-carboxylated osteocalcin (COC) so obtained is compared to the mean concentration of gamma-carboxylated osteocalcin (mean COC) in similar body fluid samples of the population of the same age and sex. Alternatively, the determined ratio COC/IOC or COC/TOC for said person, is compared to the mean ratio COC/IOC or COC/TOC, (mean ratio COC/IOC or mean ratio COC/TOC) determined from measurements in similar body fluid samples of the population of the same age and sex. A measured COC that is lower than the mean COC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. Preferably, a determined ratio COC/TOC that is lower than the mean ratio COC/TOC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person. The invention concerns further kits for use in the assessment according to this invention.
REFERENCES:
patent: 4 008 546 (1989-03-01), None
patent: 0 557 663 (1993-01-01), None
patent: WO 99/09058 (1999-02-01), None
Koyama et al. J. Immunological Methods 1991 vol. 139: 17-23 (Abstract).
Obrant, Karl J. et al., “The Proportion of Carboxylated to Total or Intact Osteocalcin in Serum Discriminates Warfarin-Treated Patients from Control Subjects,”J. Bone and Mineral Res.4:555-569 *(1888), with abstract.
BIOSIS Abstract No. 92041118 (1991).
BIOSIS Abstract No. 206737 (1998).
CAPLUS Abstract No. 812331 (1997).
Käkönen Sanna-Maria
Lövgren Timo
Luukinen Heikki
Pettersson Kim
Väänänen H. Kalervo
Cheu Jacob
Le Long V.
Rothwell Figg Ernst & Manbeck
LandOfFree
Method for prediction of bone fractures by osteocalcin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for prediction of bone fractures by osteocalcin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for prediction of bone fractures by osteocalcin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3498452